SNSE
Sensei Biotherapeutics Inc (SNSE)
Healthcare • NASDAQ • $23.40-1.80%
- Symbol
- SNSE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $23.40
- Daily Change
- -1.80%
- Market Cap
- $31.38M
- Trailing P/E
- N/A
- Forward P/E
- -20.89
- 52W High
- $36.76
- 52W Low
- $5.26
- Analyst Target
- $50.00
- Dividend Yield
- N/A
- Beta
- -0.18
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headqua…
Company websiteResearch SNSE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.